Viking Therapeutics Receives $87.80 Average Price Target

Analysts give the biotech company a 'Moderate Buy' rating on its pipeline of metabolic and endocrine disorder treatments.

Apr. 5, 2026 at 5:34am

Got story updates? Submit your updates here. ›

Viking Therapeutics, Inc. (NASDAQ:VKTX) has received a 'Moderate Buy' consensus rating from 14 research firms covering the company, with an average 1-year price target of $87.80. The San Diego-based biotech company is developing novel therapies for conditions like non-alcoholic steatohepatitis (NASH), dyslipidemia, type 2 diabetes, and muscle wasting disorders.

Why it matters

Viking Therapeutics' pipeline of small-molecule treatments targeting hormone signaling pathways has generated significant interest from Wall Street analysts, who see the company's lead programs VK2809 and VK5211 as potential blockbusters in their respective therapeutic areas. The average price target suggests analysts believe the stock has substantial upside potential.

The details

The 14 analysts covering Viking Therapeutics have a range of recommendations, with one 'sell' rating, four 'hold' ratings, five 'buy' ratings, and four 'strong buy' ratings. Several firms, including Weiss Ratings, BTIG Research, Morgan Stanley, and HC Wainwright, have issued positive notes on the company's drug candidates and outlook.

  • Viking Therapeutics last reported quarterly earnings on February 11, 2026.
  • The company's CFO and COO sold a combined 115,322 shares in early January 2026.

The players

Viking Therapeutics, Inc.

A clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders. The company is headquartered in San Diego, California.

Greg Zante

The Chief Financial Officer of Viking Therapeutics who sold 57,661 shares in early January 2026.

Marianna Mancini

The Chief Operating Officer of Viking Therapeutics who sold 57,661 shares in early January 2026.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, Grocery employee

The takeaway

Viking Therapeutics' promising pipeline of metabolic and endocrine disorder treatments has garnered strong interest from Wall Street, with analysts projecting significant upside potential for the stock based on the company's clinical progress and leadership team.